Hepatitis C

Through a collaboration with the University of Bristol, we develop dynamic, deterministic models of hepatitis C and HIV transmission among injecting drug users (IDUs), in order to guide policymaking surrounding hepatitis C and HIV treatment and prevention. Our models have been used to: examine the impact1 2 and cost-effectiveness3 of using HIV or HCV antiviral treatment for IDUs as a means of primary prevention of HIV/HCV among the IDU population; explore trends in HIV and HCV prevalence among IDUs in different settings3 4 5 6; determine the current and future impact of prevention interventions such as opiate substitution therapy and needle and syringe programmes7 2 8; evaluate the cost-effectiveness of interventions to increase HCV testing among IDUs9 or the levels of syringe distribution10 11 12.


Peter Vickerman, Natasha Martin


  1. Martin, N.K., Vickerman, P., Foster, G.R., Hutchinson, S., Goldberg, D., and Hickman, M. 2011. Can Antiviral Therapy for Hepatitis C Reduce the Prevalence of HCV Among Injecting Drug User Populations? A Modelling Analysis of its Prevention Utility. J Hep. 54(6):1137-44.
  2. Degenhardt, L., Mathers, B., Vickerman, P., Rhodes, T., Latkin, C., Hickman, M. (2010) Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 376: 285-301.
  3. Martin, N.K., Vickerman, P., Miners, A., Foster, G.R., Hutchinson, S., Goldberg, D., and Hickman, M. 2012. The cost-effectiveness of HCV antiviral treatment for injecting drug user populations. Hepatology 55(1):49-57. Vickerman, P., Martin , N.K., and M Hickman. Understanding the trends in HIV and hepatitis C prevalence amongst injecting drug users in different settings—Implications for intervention impact. Drug Alcohol Depend. (2011), doi:10.1016/j.drugalcdep.2011.10.032.
  4. Vickerman, P. Hickman, M., May, M., Kretzschmar, M., Wiessing L. (2010) Can HCV prevalence be used as a measure of injection-related HIV-risk in populations of injecting drug users? An ecological analysis. Addiction 105(2):311-8.
  5. Vickerman, P., Platt, L., Hawkes, S. (2009) Modelling the transmission of HIV and HCV amongst injecting drug users in Rawalpindi, a low HCV prevalence setting in Pakistan. STI 85 supp 2: ii23-30.
  6. Vickerman P., Hickman M., Judd A. (2007) Modelling the impact of hepatitis C transmission of reducing syringe sharing: London case study. International Journal of Epidemiology 36: 396-405.
  7. Vickerman P., Martin, N.K., and Hickman, M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in HCV prevalence? Model projections for different epidemic scenarios. (submitted).
  8. Vickerman P., Hickman M., Rhodes T., Watts C. (2006) Model projections on the required coverage of syringe distribution to prevent HIV epidemics among injecting drug user. JAIDS 42: 355-361.
  9. Martin, N.K., Miners, A., and Vickerman, P. 2012. Assessing the cost-effectiveness of interventions aimed at promoting and offering hepatitis C testing to injecting drug users: An economic modeling report. National Instititue for Clinical Excellence (NICE) public health report. (In publication).
  10. Guinness, L., Vickerman, P., Quayyum, Z., Foss, A., Watts, C. et al. (2009) The cost-effectiveness of intervening early and consistently: harm reduction in Bangladesh. Addiction 105(2):319-28
  11. Vickerman, P., Kumaranyake, L., Balakireva, O., Guinness, L., Artyukh, O., Semikop, T., Yaremenko, O., Watts, C. (2006) The cost-effectiveness of expanding harm reduction activities for injecting drug users in Odessa, Ukraine. STD 33 (10) supplement: S89-S102
  12. Kumaranyake, L., Vickerman, P., Walker, D., Samoshkin, S., Romantsov, V., Zviagin, V., Emelyanova, Z., Watts, C. (2004) The cost-effectiveness of HIV preventive measures among injecting drug users in Svetlogorsk, Belarus. Addiction 99: 1565-1576

Comments are closed.